Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.61 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736902 | 1.00 | PDE4D (0.61) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL9548618 | 0.89 | AHCY (0.53) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL9548611 | 0.89 | AHCY (0.53) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL31652941 | 0.87 | AHCY (0.54) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL30689530 | 0.87 | AHCY (0.54) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL21614181 | 0.87 | AHCY (0.54) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL24195283 | 0.87 | AHCY (0.54) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL20670946 | 0.87 | AHCY (0.54) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL26125834 | 0.86 | PDE4D (0.58) | PDE4DPDE3APNPLMNATP53 | |
| SCHEMBL17234114 | 0.85 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178128-A1 | METHODS OF TREATING MEDICAL CONDITIONS USING ISLATRAVIR OR A RELATED COMPOUND | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022271878-A1 | 4-ETHYNYL-3-HYDROXY-TETRAHYDROFURANYL-ADENINE PHOSPHORAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220010316-A1 | ENGINEERED PURINE NUCLEOSIDE PHOSPHORYLASE VARIANT ENZYMES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-01-13 | — | — | US | disclosed |
| US-11162105-B2 | Engineered purine nucleoside phosphorylase variant enzymes | CODEXIS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | PDE4D 2141/4885PDE3A 2953/4885PNP 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.